AICD: an integrated anti-inflammatory compounds database for drug discovery

Abstract

Systemic or local inflammation drives the pathogenesis of various human diseases. Small compounds with anti-inflammatory properties hold great potential for clinical translation. Over recent decades, many compounds have been screened for their action against inflammation-related targets. Databases that integrate the physicochemical properties and bioassay results of these compounds are lacking. We created an “Anti-Inflammatory Compounds Database” (AICD) to deposit compounds with potential anti-inflammation activities. A total of 232 inflammation-related targets were recruited by the AICD. Gene set enrichment analysis showed that these targets were involved in various human diseases. Bioassays of these targets were collected from open-access databases and adopted to extract 79,781 small molecules with information on chemical properties, candidate targets, bioassay models and bioassay results. Principal component analysis demonstrated that these deposited compounds were closely related to US Food and Drug Administration-approved drugs with respect to chemical space and chemical properties. Finally, pathway-based screening for drug combination/multi-target drugs provided a case study for drug discovery using the AICD. The AICD focuses on inflammation-related drug targets and contains substantial candidate compounds with high chemical diversity and good drug-like properties. It could be serviced for the discovery of anti-inflammatory medicines and can be accessed freely at http://956023.ichengyun.net/AICD/index.php .

Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products

“…ichengyun.net/AICD/index.php.) has recorded over 79,781 small molecules of the therapeutic potential and a total of 232 inflammation-related targets [232]. Ten out of 2,892 natural products showed potent efficacy as anti-inflammatory drug lead candidates when assessed for their anti-inflammatory activity in the prediction model constructed using iterative stochastic elimination algorithm.…”

COVID-19 and Traumatic Brain Injury (TBI); What We Can Learn From the Viral Pandemic to Better Understand the Biology of TBI, Improve Diagnostics and Develop Evidence-Based Treatments

“…But the importance lies is the context in which this cytokine is found. Numerous databases containing searchable data of various aspects of inflammation, anti-inflammatory molecules, molecular signaling, and disease phenotypes are available and can be queried for molecular networks using systems biology approaches ( 51 , 52 ). BD approaches in TBI have been hampered by insufficient volumes of data and lack of data standards ( 46 , 47 , 53 ), but the benefits of using BD can be transformational in identifying pharmacological and other therapies for TBI-induced disorders.…”

Design, Synthesis, In Silico and In Vitro Studies for New Nitric Oxide-Releasing Indomethacin Derivatives with 1,3,4-Oxadiazole-2-thiol Scaffold

“…When inflammation persists for a long time, holding the body in a constant state of alert, it may become chronic, with a negative impact on tissue and organs [7]. The clinical consequences of chronic inflammation-driven damage can be severe and include increased risk of many chronic diseases such as: rheumatoid arthritis [8], inflammatory bowel disease [9], metabolic disorders (diabetes mellitus and obesity) [10][11][12], cardiovascular disorders (ischemic heart disease, atherosclerosis) [13,14], neurodegenerative diseases (Parkinson's and Alzheimer's disease) [15][16][17] and cancer [18], many of these conditions being life-threatening [19,20]. The current use of NSAIDs in the European Union is associated with a 19% increased risk of hospital admissions for heart Int.…”